Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASURE: TW001 (Oral Edaravone) in Mild Alzheimer's Disease
NCT05323812Phase 2Completed
- Sponsor
- Treeway
- Start
- Mar 2023
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial in Alzheimer's disease (AD) comparing TW001 with Placebo (2 arms). Primary endpoints: Nature, frequency and severity of adverse events at 4 months, Plasma oxidative stress biomarkers at 4 months and 1 more. Started Mar 2023; status: completed.
02
Drugs
edaravone
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT05323812.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05323812.